Drug Profile
Research programme: macrocyclic peptide therapeutics - PeptiDream/Shionogi
Latest Information Update: 28 Mar 2020
Price :
$50
*
At a glance
- Originator PeptiDream; Shionogi
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for research development in Unspecified in Japan
- 03 May 2019 PeptiDream and Shionogi complete Peptide Discovery Platform System (PDPS) technology transfer agreement
- 12 Jun 2017 PeptiDream non-exclusively licenses its Peptide Discovery Platform System (PDPS) to Shionogi for use in development of macrocyclic peptides